| |
| |
|
| Insider
Information: |
Nader Francois |
| Relationship: |
Director |
| City: |
Salt Lake City |
| State: |
UT |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
27,356 |
|
|
Indirect Shares
|
386,932 |
|
|
| Direct
Value |
$1,206,384 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
414,288 |
|
|
| Total
Value |
$1,206,384 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
NPS Pharmaceuticals Inc |
NPSP |
President, CEO and Dir... |
2015-02-21 |
0 |
|
0 |
Premium* |
|
|
Baxalta Inc |
BXLT |
Director |
2016-06-03 |
0 |
2015-07-27 |
0 |
Premium* |
|
|
Acceleron Pharma Inc |
XLRN |
Director |
2021-01-29 |
6,749 |
2017-03-02 |
0 |
Premium* |
|
|
Alexion Pharmaceuticals Inc |
ALXN |
Director |
2021-07-21 |
0 |
2017-11-29 |
0 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director |
2019-06-24 |
0 |
2021-01-22 |
0 |
Premium* |
|
|
Tourmaline Bio |
TRML |
Director |
2022-07-25 |
0 |
2022-07-25 |
386,932 |
Premium* |
|
|
Moderna, Inc. |
MRNA |
Director |
2022-05-10 |
20,607 |
2022-04-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
66 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2015-02-13 |
4 |
D |
$45.88 |
$578,088 |
D/D |
(12,600) |
276,955 |
0 |
- |
|
| ALXN |
Alexion Pharmaceuticals I... |
Director |
– • – |
2021-07-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(13,921) |
0 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2010-02-03 |
4 |
S |
$3.37 |
$65,210 |
D/D |
(19,350) |
149,658 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2009-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
103,361 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• • – |
2013-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
20,299 |
214,943 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2014-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
20,300 |
228,380 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2015-02-07 |
4 |
A |
$0.00 |
$0 |
D/D |
20,301 |
233,656 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2013-09-26 |
4 |
OE |
$5.05 |
$103,521 |
D/D |
20,342 |
237,820 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• – – |
2009-10-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,533 |
124,794 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• – – |
2008-04-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,534 |
90,884 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• • – |
2013-02-19 |
4 |
D |
$8.01 |
$173,208 |
D/D |
(21,624) |
236,126 |
0 |
- |
|
| MRNA |
Moderna, Inc. |
Director |
• • – |
2022-05-10 |
4 |
OE |
$18.87 |
$435,897 |
D/D |
23,100 |
23,803 |
0 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2019-06-24 |
4 |
A |
$0.00 |
$0 |
I/I |
23,747 |
23,747 |
0 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • – |
2021-01-22 |
4 |
D |
$0.00 |
$0 |
I/I |
(23,747) |
0 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2014-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,301 |
245,423 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2015-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,301 |
289,555 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2011-11-09 |
4 |
B |
$5.36 |
$160,800 |
D/D |
30,000 |
132,690 |
2.81 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• – – |
2012-12-21 |
4/A |
A |
$0.00 |
$0 |
D/D |
30,450 |
165,111 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-21 |
4 |
B |
$3.72 |
$135,780 |
D/D |
36,500 |
138,500 |
2.39 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2013-09-27 |
4 |
OE |
$5.71 |
$258,019 |
D/D |
43,458 |
131,278 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2013-09-27 |
4 |
AS |
$32.36 |
$1,406,118 |
D/D |
(43,458) |
87,820 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, CEO and Director |
• • – |
2015-02-12 |
4 |
OE |
$0.00 |
$151,769 |
D/D |
43,804 |
270,197 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
SVP & COO |
• – – |
2008-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
69,350 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President & CEO |
• • – |
2013-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
257,750 |
0 |
- |
|
| TRML |
Tourmaline Bio |
Director |
– • – |
2022-07-19 |
4 |
B |
$3.52 |
$176,000 |
D/D |
50,000 |
50,000 |
2.39 |
- |
|
66 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
